A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106

Trimmomatic: a flexible trimmer for Illumina sequence data

Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548

The Sequence Alignment/Map format and SAMtools

Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041

Integrative genomics viewer

Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390

A method and server for predicting damaging missense mutations.

Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194

Integrating single-cell transcriptomic data across different conditions, technologies, and species

Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174

Complex heatmaps reveal patterns and correlations in multidimensional genomic data

Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,037

Analysis of protein-coding genetic variation in 60,706 humans

Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587

The mutational constraint spectrum quantified from variation in 141,456 humans

Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2308-7 · Cited by 9,434

The Ensembl Variant Effect Predictor

McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099

Exploring the Evolving Significance of lncRNA TUG1-mediated Signaling Pathways in Breast Cancer

Dari, M. A. G., Anbiyaiee, A., Moghanibashi, M., Jafari, R. M., Moramezi, F., & Farzaneh, M. (2024) · Current Signal Transduction Therapy · doi:10.2174/0115743624264761231212055008 · Cited by 2

Patient-Derived Xenografts: A Valuable Preclinical Model for Drug Development and Biomarker Discovery

Weng, T., Jenkins, B. J., & Saad, M. I. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3858-3_3 · Cited by 1

Assessing the Efficacy and Feasibility of Conditioned Medium as a Culture Reagent for Tumor Organoid Culture: A Comprehensive Evaluation

Hu, L., Xie, S., You, M., Xing, H., Zhang, B., Zhu, X., & Bian, L. (2024) · Journal of Organoid and Bioscience · doi:10.62714/kkdl3357 · Cited by 1

Mitochondrial metabolism-related features guiding precision subtyping and prognosis in breast cancer, revealing FADS2 as a novel therapeutic target

Kang, Y., Meng, Y., Jin, J., Dai, Y., Li, F., Chen, N., Xie, H., & Cui, Y. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102330 · Cited by 1

Predicting and Optimizing Synergistic Drug Combinations for Breast Cancer Treatment Using Machine Learning

Jain, D., Upreti, K., Tak, T. K., Date, S. S., Kshirsagar, P. R., Jain, R., & Agrawal, R. (2025) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001244 · Cited by 1

ACSS2-mediated metabolic-epigenetic crosstalk drives Fulvestrant resistance and represents a novel therapeutic target

Mogol, A. N., Yoo, J. Y., Eve, A. A., Goel, M., Dutton, D. J., Schane, C. P., Lam, A., Dutta, D., Barnick, B., Erdogan, E. D., et al. (2026) · npj Breast Cancer · doi:10.1038/s41523-026-00987-0 · Cited by 1

Automation in microinjection for zebrafish pericardial space with image-based motion control and batch agarose microplate

Lee, H.-J., Lee, H.-K., Lee, S.-W., Son, Y.-W., Shin, J., & Kim, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0333369 · Cited by 1

Discovery, preclinical safety, and efficacy characterization of SMAC mimetic S-016-1348 as a potential cancer therapeutic

Sinha, A., Nengroo, M. A., Ali, R., Khan, A. A., Dutta, H. S., Singh, A., Saini, K. K., Tripathi, K., Katekar, R. A., Rathaur, S., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.056 · Cited by 1

Extracellular matrix rigidity controls breast cancer metastasis via TYK2-mediated mechanotransduction

Hu, Z., Majeski, H. E., Mestre‐Farrera, A., Cai, S., Lalezarzadeh, A., Zhang, Y., Arimoto, K., Zhang, D., Piwnica-Worms, H. M., Fattet, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70518-9 · Cited by 1

Integration and validation of complementary ex vivo assays for functional precision oncology

Loboda, A., Paluncic, J., Freitas, M., Weidmann, M., Herter, S., Zeiser, C., Schulz, J. P., Jády, A., Blattner-Johnson, M., Autry, R. J., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01555-2 · Cited by 1

In vitro preclinical modeling of sex-specific biology and hormonal dynamics in women's health: insights across multiple organs

Tang, S., Ji, J., Gulati, A., Man, Y., Belgur, C., Junaid, A., & Ingber, D. E. (2026) · Frontiers in Global Women s Health · doi:10.3389/fgwh.2026.1878598 · Cited by 1

Multi‐regional Organoid Biobank Reveals FAK‐ACSL1‐Driven Doxorubicin‐Resistance and Predictive Biomarkers in Breast Cancer

Xu, H., Qin, Z., Yang, J., Zhang, B., Cao, M., Wang, P., Wang, Z., Cheng, J., Lq, W., Liu, H., et al. (2026) · Advanced Science · doi:10.1002/advs.76541 · Cited by 1

LncPRESS1 promotes the progression and cisplatin resistance of breast cancer through upregulation of ENO1 and activation of glycolysis

Ke, L., Gao, W., Leng, Y., Chen, J., Chen, H., Li, S., Zhang, Y., & Luo, L. (2025) · Cell Division · doi:10.1186/s13008-025-00167-9 · Cited by 1

Insights from Genomic Sequencing of Preclinical Breast Cancer Models Establish Human Parallels to Increase Therapeutic Applicability

Schulte, A., & Andrechek, E. R. (2026) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-026-09599-7 · Cited by 1

Co-occurrence of transcriptionally distinct persister cell states underpins neoadjuvant therapy resistance in triple‑negative breast cancer

Zhang, Y., Moughari, F. A., Mavrommati, I., Doleschall, N. J., Moore, K., Muirhead, G., Srinivasan, R., Gong, P., Lei, J. T., Fleming, A., et al. (2026) · Genome Medicine · doi:10.1186/s13073-026-01643-9 · Cited by 1

Necroptosis triggers inflammatory interferon signatures in patient-derived metastatic breast cancer organoids

Wächtershäuser, K. N., Schneider, J. V., Geßner, A., Andrieux, G., Kur, I.-M., Duschek, N., Weigert, A., Boerries, M., Rieger, M. A., Stelzer, E. H. K., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02755-9 · Cited by 1

Decoding triple negative breast cancer bone metastasis: from 3D bioprinted models to clinical translation

Xu, J., Kang, Y. Y., Kedong, S., Fan, J., & Liu, Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04655-0 · Cited by 1

Determination of drug sensitivity in patient derived models of breast cancer by multiparametric quantitative phase imaging

Polanco, E. R., Moustafa, T. E., Balcioglu, O., Scherer, S. D., Cortes-Sanchez, E., Remick, S. M., Spike, B. T., Welm, A. L., Welm, B. E., Bernard, P. S., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-16752-2 · Cited by 1

Time-Dependent Multimechanistic Antitumor Effects of Olive Oil Phenolics in a Triple-Negative Breast Cancer Mouse Model

Madelou, N. A., Καπετάνου, Μ., Papakonstantinou, K., Koutsoni, O. S., Kakazanis, Z., Melliou, E., Magiatis, P., Zoumpourlis, V. C., Gonos, E. S., & Boleti, H. (2026) · Nutrients · doi:10.3390/nu18172756 · Cited by 1

Transmissible Animal Tumors as Models for Cancer Research

Ahmed, O. M., Zaky, M. Y., Chen, P., & Yassin, N. Y. S. (2022) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-1282-5_62-1 · Cited by 1

New insights about organoids as model of study for breast cancer research

Macías-Paz, I. U., Rivera-Arenas, A., Reyna‐Beltrán, E., & Tavera-Tapia, A. (2022) · Gaceta Mexicana de Oncología · doi:10.24875/j.gamo.22000110 · Cited by 1

Modeling cancer dependency with deep graph modelsPreprint

Fu, H., Zhao, B., & Wang, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.26.582022 · Cited by 1

Multimodal profiling unveils a reversible breast basal-like cell state in AKT-inhibitor resistant tumoursPreprint

Ratcliffe, C. D. H., Sparks, H., Boezio, G. L. M., Alexandrov, Y., Jenkins, R. P., Marois, A. L., Soro-Barrio, P., Moughari, F. A., Hulme, H., Lee, R. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.06.658331 · Cited by 1

Microtubule Inhibition Triggers MYC-Mediated Immunogenic Cell Death in Breast CancerPreprint

Liu, R., Aung, J., Peura, A., Hiltunen, A. O., Id, L., Savelius, M., Peltonen, M., Turpin, R., Salmelin, N., Anttila, J. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.26.671755 · Cited by 1

Clonal morphology-guided combination therapies overcome heterogeneity-driven drug tolerancePreprint

Li, X. W., Liu, L., Yan, Y., Yang, M., Luo, L., Jiang, Y., & Ren, W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.31.703021 · Cited by 1

VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models

Allen, V., Coulombe, J., Zhao, H., Kreps, L. M., Cook, D. P., Pryce, B. R., Clemons, M. J., Vanderhyden, B. C., Gray, D. A., & Addison, C. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01778-7

Transmissible Animal Tumors as Models for Cancer Research

Ahmed, O. M., Zaky, M. Y., Chen, P., & Yassin, N. Y. S. (2023) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-3824-5_62

Decision letter: Transferred mitochondria accumulate reactive oxygen species, promoting proliferation

(2023) · eLife · doi:10.7554/elife.85494.sa1

Data from Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics

Bhatia, S., Kramer, M., Russo, S., Naik, P. K., Arun, G., Brophy, K., Andrews, P. W., Fan, C., Perou, C. M., Preall, J. B., et al. (2023) · doi:10.1158/0008-5472.c.6513885.v1

Data from Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer

Leto, S. M., Ferri, M., Sassi, F. P., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · doi:10.1158/1078-0432.c.6533128.v1

Data from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data

Fisher, N. C., Byrne, R. M., Leslie, H., Wood, C., Legrini, A., Cameron, A. J., Ahmaderaghi, B., Corry, S. M., Malla, S. B., Amirkhah, R., et al. (2023) · doi:10.1158/1078-0432.c.6532604

Data from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data

Fisher, N. C., Byrne, R. M., Leslie, H., Wood, C., Legrini, A., Cameron, A. J., Ahmaderaghi, B., Corry, S. M., Malla, S. B., Amirkhah, R., et al. (2023) · doi:10.1158/1078-0432.c.6532604.v1

piTracer - Automatic reconstruction of molecular cascades for the identification of synergistic drug targetsPreprint

Gomari, D. P., Achkar, I. W., Benedetti, E., Tabling, J., Halama, A., & Krumsiek, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.08.535933

Data from Optimizing precision medicine for breast cancer brain metastases with functional drug response assessment.

Morikawa, A., Li, J., Ulintz, P., Cheng, X., Apfel, A. M., Robinson, D. R., Hopkins, A., Kumar‐Sinha, C., Wu, Y., Serhan, H. A., et al. (2023) · doi:10.1158/2767-9764.c.6689056.v1

Data from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment

Morikawa, A., Li, J., Ulintz, P., Cheng, X., Apfel, A. M., Robinson, D. R., Hopkins, A., Kumar‐Sinha, C., Wu, Y., Serhan, H. A., et al. (2023) · doi:10.1158/2767-9764.c.6689056

Computational precision therapeutics and drug repositioning

Powell, R. T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00063-0

Multiparametric quantitative phase imaging as a tool to assess breast cancer response to therapy in patient-derived models

Moustafa, T. E., Polanco, E. R., Remick, S., Balcioglu, O., Scherer, S. D., Cortes-Sanchez, E., Spike, B. T., Welm, B. E., Bernard, P. S., & Zangle, T. A. (2024) · Quantitative Phase Imaging · doi:10.1117/12.3004844

A robust protocol for the systematic collection and expansion of cells from ER + breast cancer tumors and their matching tumor-adjacent tissuesPreprint

Topolnitska, D., Moreno, C. L., Paiva, A., Buchel, E. W., Safneck, J. R., & Raouf, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.09.598157

An Overview of the Bench to Bedside Models of Breast Cancer in the Era of Cancer Immunotherapy

Kwan, A., Stark, K., Allen, R. J., Ottewell, P. D., & Muthana, M. (2024) · Medical Research Archives · doi:10.18103/mra.v12i6.5514

Patient-derived Organoids as a Tool for Advancing Precision Immuno-oncology

Than, X. Y., Ong, T. T., & Chow, E. K. (2024) · World Scientific Annual Review of Cancer Immunology · doi:10.1142/s2972389224300019

Circulating tumor cells as a clinical, diagnostic, and prognostic biomarker in breast cancer

Gandhi, K., & Sharma, G. (2025) · Breast Disease · doi:10.1177/15581551241296776

Cloud Computation Methods to Accelerate Breast Cancer Drug Discovery through Molecular Modeling

Kobi, J., & Nchaw, A. N. (2025) · doi:10.38124/ijisrt/25may2204

Personalizing Breast Cancer Treatment with Patient-derived Xenografts (PDX): Analyzing PDXs Fidelity, Stability, and Intra-Tumoral HeterogeneityPreprint

Sobarzo, A., Msamra, M., Elkin, R., Agassi, R., Aizenberg, N., Oh, J. H., Delgado, B., Norton, L., & Kessous, R. (2025) · Research Square · doi:10.21203/rs.3.rs-6730867/v1

Vision Evaluation of Patient-Derived Organoids for Personalised Medicine

Vogt, H., Gaillard, M., & Green, S. (2025) · SpringerBriefs in philosophy · doi:10.1007/978-3-031-85535-1_4

Diseases of the Matrix and the Role of SLRPs in Inflammatory Catabolism

Lama, P., & ADAMS, M. A. (2025) · Springer eBooks · doi:10.1007/978-981-96-7890-7_2

The power of connection—enabling collaborative, multimodal data analysis at petabyte scale to advance understanding of oncology

Davis‐Dusenbery, B. N., Fisher, C. R., Beck, R., & Worman, Z. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780192867636.003.0018

Emerging imaging biomarkers in breast cancer: transforming screening, staging, and therapeutic assessment

Tripathi, S., Sharma, Y., & Kumar, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33653-9.00006-5

Patient derived xenograft models of hormone receptor positive and HER2 negative breast cancer from Indian patients

Gandhi, K., Chaubal, R., Talker, E., Aadhi, J. C., Pandey, S., Mukhare, R., Kadam, A., Singh, A., Gurav, M., Parab, P. A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-22361-z

Establishment of a metastatic patient-derived xenograft model of breast carcinoma

Boháč, M., Čumová, A., Cihova, M., Trnkova, L., Sedláčková, E., Tran, M. T., Novotna, N., Karaba, M., Dyttert, D., Durdík, Š., et al. (2025) · Neoplasma · doi:10.4149/neo_2025_250627n283

The non-kinase function of CDK6 is a key driver of acquired resistance to CDK4/6 inhibitors in Estrogen Receptor-positive breast cancerPreprint

Udden, S. M. N., Jiang, B., Pandey, K., Lewis, C. M., Sahoo, S., Williams, N. S., & Alluri, P. G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.11.687883

Single-cell RNA sequencing reveals age-related heterogeneity in the tumor microenvironment of breast cancer patients

Li, Z., Ji, F., An, M., Kou, S., Zhao, Z., Yu, J., Liu, B., & Shang, F. (2025) · Scientific Reports · doi:10.1038/s41598-025-24720-2

Modelling anti-estrogen resistance in estrogen receptor-positive breast cancer: molecular mechanisms and emerging therapeutic strategies

Hamama, R., Alasheev, A. Y., Petersen, E. V., & Maximov, P. Y. (2025) · ONCOLOGIE · doi:10.1515/oncologie-2025-0365

Additional file 1 of An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer

Scherer, S. D., Riggio, A. I., Haroun, F., DeRose, Y. S., Ekiz, H. A., Fujita, M., Toner, J., Zhao, L., Li, Z., Oesterreich, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16909767

Additional file 2 of Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma

Thorel, L., Morice, P., Paysant, H., Florent, R., Babin, G., Thomine, C., Perréard, M., Abeilard, E., Giffard, F., Brotin, É., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24264744

Additional file 1 of Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer

Peterson, J. R., Cole, J. A., Pfeiffer, J. R., Norris, G. H., Zhang, Y., Lopez-Ramos, D., Pandey, T., Biancalana, M., Esslinger, H. R., Antony, A. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26588484

Additional file 1 of Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers

Derouane, F., Desgres, M., Moroni, C., Ambroise, J., Berlière, M., Bockstal, M. V., Galant, C., van Marcke, C., Vara-Messler, M., Hutten, S. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25248790

Additional file 1 of Establishing conditions for the generation and maintenance of estrogen receptor-positive organoid models of breast cancer

Oliphant, M. U. J., Akshinthala, D., & Muthuswamy, S. K. (2024) · Figshare · doi:10.6084/m9.figshare.26699558

ヒト食道扁平上皮がんオルガノイドモデルの確立

佐藤, 卓. (2025) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.21.347

In Vivo Modelling of Human Breast Cancer Using Cell‑Line and Patient‑Derived Xenografts: Advances and Future Directions

Dey, S., De, D., & Saha, S. (2026) · Current Breast Cancer Reports · doi:10.1007/s12609-025-00630-0

Computational and Experimental Verification of Cabozantinib Targeting DDX11 to Inhibit DNA Damage Repair in Liver Cancer

Li, L., Huang, Z., Liu, Z., Zhong, J., Li, D., & Liu, L. (2026) · ACS Omega · doi:10.1021/acsomega.5c10093

Biomimetic hydrogel for the construction of patient-derived bladder cancer organoids with aggressive growth

Zhang, J., Wang, J., Hu, X., Jia, W., Zhou, Z., Kadeerhan, G., Guo, W., Tian, J., Guo, H., Guo, L., et al. (2026) · iScience · doi:10.1016/j.isci.2026.114786

Xenograft-Derived Human Breast Cancer Organoids Can Form Chimeras with Host Mouse Mammary Epithelial Cells Which Promote Tumor Cell Proliferation

Uematsu, H., Saito, C., Kondo, J., Onuma, K., Coppo, R., Endo, H., Nakayama, T., Yoshidome, K., Nomura, T., Kohara, A., et al. (2026) · Organoids · doi:10.3390/organoids5010006

Ex vivo drug sensitivity testing predicts treatment outcomes in advanced ovarian cancer

Labrosse, K. B., Lombardo, F. C., Bartoszek, E. M., Sauteur, L., Tanner, N., Tanna, T., Wolf, A., TUNKOVÁ, B., Kašíková, L., Fedier, A., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01321-4

A Pan-Cancer Ex Vivo Drug Screen Atlas for Functional Precision OncologyPreprint

Pichotta, K., White, J. B., Quinn, J. F., Markus, A., Tosh, C., de Mathelin, A., Coyne, E. M., Huang, F., & Tansey, W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.14.705918

Tumor Organoids and Organs-on-a-Chip Platform to Properly Resemble Natural Killer Cells Infiltration and Crosstalk with Cancer Cells

Palamà, M. E. F., Gay-Para, T. F., Borka, G., Boucherit, N., Gorvel, L., & Scaglione, S. (2025) · Springer eBooks · doi:10.1007/978-3-662-68816-8_51-1 · Cited by 1

Developing Mammary Gland Models for Biomedical Applications

Zhao, J., Lin, X., Zhang, H., & ZHAO, Y. (2026) · Research · doi:10.34133/research.1240

Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies

Hutten, S. J., Chao, X., Badoux, M., Eijkman, T., Sheinman, M., de Bruijn, R., Herencia-Ropero, A., Llop‐Guevara, A., Lutz, C., Wesseling, J., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.ads9088

An Experimental Study into the Photodynamic/Sonodynamic Therapy of Triple-Negative Breast Cancer Mediated by the Novel Nano-Photonic Sensitizer NBDPBr Nanoparticles

Huang, Q., Wang, L., Zhang, Y., Zhao, L., & Zhang, T. R. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s576927

Patient-derived organoid xenografts reveal the multifaceted role of the lncRNA MALAT1 in breast cancer progressionPreprint

Aggarwal, D., Russo, S., Anderson, K. L., Floyd, T., Utama, R., Rouse, J. A., Naik, P. K., Pawlak, S. A., Iyer, S. V., Kramer, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.02.716096

Identification and credentialing of patient-derived xenograft models of invasive lobular carcinoma

Hooda, J., Atkinson, J. M., Shah, O. S., Yates, M. E., Brown, D. D., DeBerry, M., Cairo, S., Schiavini, P., Tsai, H.-W., Zipeto, M., et al. (2026) · Disease Models & Mechanisms · doi:10.1242/dmm.052710

Gaps and paths forward in cancer pharmacology and translational research

Hughes, E., Davenport, L. L., Zdyrski, C., Pawlak, A., Mochel, J. P., & Douglass, E. F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1779049

Natural Killer Cell-Derived Extracellular Vesicles Exhibit Cytotoxicity Against Bulk Tumor Cells and Cancer Stem Cells in Triple-Negative Breast Cancer

Kirkby, M., Bissonnette, F. S.-D., Diab, M. D., Mediratta, K., Korobkow, A., Humber, J., Han, P., Muradia, G., Ardolino, M., Lee, S.-H., et al. (2026) · Nanomaterials · doi:10.3390/nano16090525

Epithelial mesenchymal transition initiates precancer states in BRCA1 mutation carriersPreprint

Bar-Hai, N., Ben-Yishay, R., Arbili-Yarhi, S., Bernstein‐Molho, R., Goldinger, G., Balint‐Lahat, N., Menes, T. S., Herman, N., Noy, V., Mansour, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.06.723061

Research progress on precision targeted therapy strategies for breast cancer based on tumor microenvironment

Luo, Y., Xie, P., Yang, S., Qu, P., Hou, L., & Yi, Q. (2026) · iScience · doi:10.1016/j.isci.2026.116000

Circulating tumour cell-derived xenograft as a preclinical platform for metastatic breast cancer

Kahounová, Z., Hrušková, M., Drápela, S., Naar, O., Víchová, R., Navrátil, J., Fabián, P., Kokas, F. Z., Hampl, A., Bouchal, J., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03468-0

Breast cancer organoids: a precision platform for modeling heterogeneity and advancing personalized therapy

Yang, Y., Yang, J., Liang, Y., & Yang, Q. (2026) · Molecular and Digital Medicine · doi:10.1016/j.mdmed.2026.100004

Genome Organizer SATB1 selectively activates a defined subset of EMT genes driving metastatic breast cancerPreprint

Kohwi, Y., Vayn, Y., Grange, M., Ho, B., Heditsian, D. M., & Kohwi-shigematsu, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.29.728584

Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy–Resistant Breast Cancer

Pal, P., Chitkara, S., Sarpey, G. K., Vashi, A., Rawat, V., Alani, F., Zhao, H., Ata, M., Qu, J., Schiff, R., et al. (2026) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-25-0964

Comparative analysis of zebrafish, organoid, and organ-on-chip models in breast cancer research

Alzaharani, R., Alghadmi, M. A., & Amiri, M. (2026) · Biotechnology Notes · doi:10.1016/j.biotno.2026.05.001

In vivo acquired resistance to tamoxifen is associated with irreversible loss of IGF1R, upregulation of insulin receptor and enhanced sensitivity to insulinPreprint

Hoff, K. J., Periakaruppan, P., Baar, C., Irizarry, V. C. T., & Sachdev, D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.08.727558

Generating Tumor Organoid Cultures from the Lung Adenocarcinoma Cell Line

Zhao, X., He, Y., Lin, X., & Guo, B. (2026) · Journal of Visualized Experiments · doi:10.3791/70387

UI/UX-Integrated 3D Tumour Organoid Digital Platform for Precision Cancer Research: Architecture, Advances, and Clinical Translation

Chatterjee, A., & Chatterjee, T. K. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.66s.74

On-site microfluidic analysis of combined and individual drug effects on breast cancer spheroids

Vit, F. F., Wu, Y. T., Fujiwara, E., Carvalho, H. F., & de la Torre, L. G. (2026) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2026.2699821

Culture and Expansion of Circulating Tumor Cells from Breast Malignant Effusions as Organoids

Parizadeh, A., Warhadpande, S., Magbanua, M. J., & Rosenbluth, J. M. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5050-9_22

Burkitt lymphoma: current understanding, unmet needs, and research directions

Khan, A., Lopez, C., Turner, S. D., & Mbulaiteye, S. M. (2026) · Blood Advances · doi:10.1182/bloodadvances.2024015620

Serine Starvation Modulates mRNA Splicing through Translational Inhibition of SRSF Proteins

Burns, P. A., Tabatabaei, N., Selfors, L. M., Zhao, H., Sultonova, M., Rawat, V., Paulo, J. A., Sarpey, G. K., Vashi, A., Dahunsi, D. O., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-4971

A Robust Protocol for the Establishment, Expansion, Bio-Banking, and Molecular Profiling of Triple-Negative Breast Cancer Organoids

Kaur, P., Bhattacharyya, S., Gupta, P., Khare, S., Irrinki, S., & Bal, A. (2026) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001344

Artificial intelligence (AI)-enabled organoids and three-dimensional (3D) in vitro models for clinical applications and precision medicine (PM)

Pant, T., Rohra, N., Saxena, T., Pathak, S., & Ganguly, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43934-6.00028-6

Bridging In Vitro and Murine Breast Cancer Models: Advanced Imaging Across Multiscale Experimental Platforms

Terlizzi, C., Ferrara, Y., & Sarnella, A. (2026) · Cancers · doi:10.3390/cancers18152469

The coumarin derivative X6632 is a pan-ID protein inhibitor that suppresses tumor growth by targeting cancer cells and the tumor-associated microvasculaturePreprint

Götz, L. S., Deo, A., Scherer, S. D., D’Antonio, L., Weber, H. T., Sedlmeier, G., Flores, L. P. T., Kaiser, U., Far, E., Raviv, Z., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.05.742008

Tumor-Derived Model Biobanks in China: Current Status and Future Challenges

Zhang, L., Hu, Y., Li, H., Liu, Y., Xu, M., Du, X., Zhang, X., Gao, H., Zhao, X., Tian, Y., et al. (2026) · Biopreservation and Biobanking · doi:10.1177/19475535261472214

Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer

Bui, T. B. V., Wolf, D. M., Bruck, M. C., Moore, K., Lien, J., Choi, S. D. W., Warhadpande, S., Parizadeh, A., Dillon, D. A. R., Overmoyer, B. A., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102973

The Great Escape: the systems biology of endocrine resistance and lineage plasticity

Dragnev, C. P. C., Fu, Z., Huang, S., Perry, C. J., Kahn, A. M., Dinan, M. A., Tan, W. S., Leapman, M. S., Braun, D. A., Warrick, J., et al. (2026) · Endocrine Related Cancer · doi:10.1530/erc-26-0130

A Patient-Derived Xenograft Model Identifies AK1 as a Key Regulator of Metastatic Potential in Primary Triple-Negative Breast CancerPreprint

Kim, J., Lee, D., Kim, R., Heo, W., Yang, S., Lee, W., Yun, J., Lee, C., Im, S.-W., Chae, J., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10312219/v1

From comparative oncology to AI-enabled precision medicine: translational biomodels for triple-negative breast cancer

Collares, T. V., Seixas, F. K., Pessoa, C., & Dagli, M. L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1896728

Artificial intelligence-enabled analysis of electron micrographs to assess mitochondrial morphology in triple-negative breast cancer

Arriojas, A., Baek, M. L., Berner, M. J., Wang, J., Duraisingh, J., Zhurkevich, A., Hinton, A. O., Jr., Meyer, M. D., Dobrolecki, L. E., Lewis, M. T., et al. (2026) · npj Breast Cancer · doi:10.1038/s41523-026-01019-7

Laminin – myCAF interplay promotes α6-integrin-mediated breast cancer cell invasion

Virumbrales-Muñoz, M., Fertal, S. A., Lugo-Cintrón, K. M., Loken, J. R., Vazquez, Y. N., Burkel, B. M., Zhang, J., Franck, C., Ayuso, J. M., Beebe, D. J., et al. (2026) · Lab on a Chip · doi:10.1039/d5lc00711a

Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage

Satrusal, S. R., Banerjee, A., Biswas, A., Srivastava, G., Chatterjee, I., Khan, M. A., Mandal, B., Tripathi, K., Sinha, A., Verma, A., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.08.034 · Cited by 1

Polymeric nanoparticle platforms for ibrutinib delivery: tackling solubility, CYP3A4-mediated metabolism, and resistance to facilitate BTK-targeted therapy in solid tumours

Sonawane, Y. D., & Bhattacharya, S. (2026) · Therapeutic Delivery · doi:10.1080/20415990.2026.2721795

Integrated transcriptomic and immune-associated network analysis of breast cancer patient-derived organoids reveals candidate inflammatory biomarkers

Scippa, S., Balestrieri, A., Zanfardino, M., Salvatore, M., Soricelli, A., D’aiuto, M., Mossetti, G., & Ciaramella, V. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1900123

A breast cancer patient-derived xenograft and organoid platform for drug discovery and precision oncologyPreprint

Guillen, K. P., Fujita, M., Butterfield, A. J., Scherer, S. D., Bailey, M. H., Chu, Z., DeRose, Y. S., Zhao, L., Cortes-Sanchez, E., Yang, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.28.433268 · Cited by 17

Abstract SY16-02: Using patient-derived models for functional precision oncology in advanced breast cancer

Welm, A. L. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-sy16-02

Abstract P3-08-09: Development and molecular characterization of hard-to-treat breast cancer pre-clinical models to enhance precision medicine

Kuasne, H., fortier, A.-M., Busque, S., Mathien, S., Savage, P., Ramirez, C. M., Monast, A., Soleinova, M., Ömeroğlu, A., Asselah, J., et al. (2023) · Cancer Research · doi:10.1158/1538-7445.sabcs22-p3-08-09

The combination of breast cancer PDO and mini‐PDX platform for drug screening and individualized treatment

Cui, Y., Ran, R., Da, Y., Zhang, H., Jiang, M., Qi, X., Zhang, W., Niu, L., Zhou, C., Zhou, C., et al. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18374 · Cited by 14

Abstract 1273: Advancing precision oncology: Development and utilization of breast cancer PDX models for in vivo drug discovery

Trachet, E. E., Holmquist, C., Nagl, S., & Gonzales, P. M. (2025) · Cancer Research · doi:10.1158/1538-7445.am2025-1273 · Cited by 1